No doubt where they are trying to close it today. I still believe AMRN can get to $13 on a strongly positive ADCOM vote and $16 on approval in Dec. or before. If we get NCE also, $19 is probably doable. If those 3 things occur, a near-term (within 6 months) buyout moves to about a 75% probability.
I was on the same boat like you since last year, very optimistic about this company and its product Vascepa.
But it had lost 2/3 of its value from its peak last year. Now, I'm just waiting for some company to buy Amrin
in order for those shorties and hedgies to go away. Every time Amrin makes an upward move, it loses its
gains right away. The only solution is for some big pharma to take over.